Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
R42 Group is a venture capital firm based in Stanford, California, founded by Dr. Ronjon Nag, an AI pioneer and entrepreneur. Established from Dr. Nag's Family Office, the firm has a strong focus on early-stage investments in artificial intelligence, biotechnology, and deep science. R42 Group has approximately $100 million in assets under management and maintains a portfolio of around 70 companies. The firm invests directly in startups and as a limited partner in other funds, emphasizing collaboration with entrepreneurs from the idea stage through to growth.
Dr. Nag has a notable history of co-founding and advising companies that have been sold to major tech firms such as Motorola, BlackBerry, and Apple. R42 Group's investment strategy is centered on the intersection of mathematics and medicine, particularly in sectors that promise significant advancements in health and technology. The firm operates with a diverse team of experts and advisors, including professionals from prestigious institutions like Stanford University.
R42 Group targets early-stage investments across several sectors, including artificial intelligence, biotechnology, longevity, fintech, and healthcare. The firm invests at various stages, specifically pre-seed, seed, and growth equity, with a particular emphasis on collaboration with entrepreneurs to develop innovative solutions. R42 Group seeks to partner with companies that align with its values and focus on groundbreaking advancements in deep science and AI.
The firm typically engages in seed investments with check sizes around $250,000, while average investment sizes across rounds are approximately $5.82 million. R42 Group's geographic focus includes the United States, United Kingdom, and Ukraine, allowing it to tap into diverse markets and innovative ecosystems. The organization looks for founders who demonstrate a strong vision and capability to execute their ideas, valuing creativity and resilience in their pitches.
R42 Group's portfolio features a diverse array of companies, particularly in the fields of biotechnology and artificial intelligence. Notable companies include:
R42 Group has also achieved notable exits with companies sold to major players like Motorola, BlackBerry, and Apple, showcasing its ability to identify and nurture high-potential ventures.
Dr. Ronjon Nag: Founder and Managing Director. Dr. Nag is an AI pioneer with over 40 years of experience in the field. He has a history of successful ventures, including companies sold to Motorola, BlackBerry, and Apple. He also serves as an Adjunct Professor in Genetics at Stanford Medicine.
Anastasiya Giarletta: Principal at R42 Group, focusing on evaluating companies in longevity science and AI.
Dr. Artem Trotsyuk: Entrepreneur in Residence, a bioengineer and computer scientist contributing to the firm's investment strategy.
Zixuan An: Venture Associate involved in fund operations, portfolio management, and investor relations.
Dr. Joel Naor: Entrepreneur in Residence with extensive experience in the biotech sector, providing insights and guidance to portfolio companies.
R42 Group also collaborates with a team of advisors, including experts like Dr. Anne Friedlander from Stanford University and Dr. Michael Snyder, Chair of the Genetics Department at Stanford.
To pitch R42 Group, founders should visit their website at r42group.com. The pitch deck should include a clear overview of the business model, market opportunity, and team qualifications. R42 Group prefers concise and informative presentations that highlight the startup's unique value proposition. Response times may vary, but founders can expect feedback within a few weeks. Warm introductions are beneficial but not mandatory.
In 2024, R42 Group co-led a £37 million (~$47 million) Series C investment in Healx, an AI-enabled biotech firm specializing in rare diseases. This investment highlights R42 Group's commitment to supporting innovative solutions in healthcare.
Additionally, R42 Group launched a $16 million seed fund targeting 30 seed investments and 10 follow-on investments, further expanding its reach in the early-stage investment landscape.
R42 Group continues to be featured in various publications, including Longevity.Technology and UK Tech News, showcasing its active role in the venture capital space.
What are R42 Group's investment criteria?
R42 Group invests in early-stage companies and funds that align with its focus on artificial intelligence, biotechnology, and deep science. The firm looks for innovative solutions that address significant challenges in health and technology.
How can I pitch to R42 Group?
Founders can submit their pitches through R42 Group's website at r42group.com. It is advisable to include a clear business model, market analysis, and the team’s background in the pitch deck.
What makes R42 Group different from other venture capital firms?
R42 Group combines capital with strategic guidance and resources, leveraging the expertise of its team and advisors to support portfolio companies. The firm emphasizes collaboration with entrepreneurs throughout the development process.
What is the geographic scope of R42 Group's investments?
The firm primarily invests in the United States, United Kingdom, and Ukraine, allowing it to engage with diverse markets and innovative ecosystems.
What is the typical check size for investments?
R42 Group typically invests around $250,000 in seed rounds, with average investment sizes across rounds being approximately $5.82 million.
What kind of post-investment involvement does R42 Group have?
R42 Group provides ongoing support to its portfolio companies, offering strategic guidance, resources, and access to a network of experts to help drive growth and innovation.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.